FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment
The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.
UPI20d
FDA approves Spravato, first monotherapy nasal spray to treat depression
Johnson & Johnson's Spravato ... Advertisement The FDA approval of Spravato comes after a controlled study showed the nasal spray provided rapid improvement in the Montgomery-Asberg Depression ...
FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.
NBC Chicago21d
FDA approves Johnson & Johnson's nasal spray for depression as standalone treatment
The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults ... new major depression treatment to win FDA approval in more than three decades.